Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Washington René Chumbi Flores"'
Autor:
Yohann Loriot, Celine Mahier Ait Oukhatar, Benjamin Besse, S. Ortiz-Cuaran, Washington René Chumbi Flores, Jean-Yves Blay, Etienne Giroux Leprieur, Ludovic Lacroix, Mihaela Aldea, Claire Tissot, Clive Morris, Caroline Caramella, Julien Mazieres, Radj Gervais, Karen Howarth, Maurice Perol, Emma Green, Pierre Saintigny, Isabelle Monnet, C. Raynaud, Virginie Westeel, V. Avrillon, Etienne Brain, Jean-François Guichou, Camille Leonce, Maud Ngo-Camus, Anne Pradines, Frank de Kievit, Laura Mezquita, Sylvie Chabaud, Aurélie Swalduz, Cécile Jovelet, David Planchard, Luc Friboulet, N. Hoog-Labouret
Publikováno v:
Clinical Cancer Research
Purpose:The limited knowledge on the molecular profile of patients with BRAF-mutant non–small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these
Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas
Autor:
Pierre Saintingy, Solène Marteau, Anne Pradines, Karen Howarth, Emma Green, Aurélie Swalduz, Gilles Clapisson, Jean-Yves Blay, Etienne Brain, Etienne Giroux Leprieur, Frank de Kievit, C. Raynaud, Virginie Avrillon, Virginie Westeel, Isabelle Monnet, Xavier Quantin, Nathalie Hoog-Labouret, Julien Mazieres, Claire Tissot, Séverine Martinez, Radj Gervais, Clive Morris, Celine Mahier, Y. Loriot, Washington René Chumbi Flores, Sandra Ortiz-Cuaran, Séverine Neymarc, Nathalie Girerd-Chambaz, Maurice Pérol, Christelle Clément Duchene
Publikováno v:
Cancer Research. 78:1841-1841
Background: BRAF mutations occur in 2 to 3% of patients (pts) with non-small cell lung cancer (NSCLC). In these pts vemurafenib, a selective oral BRAF inhibitor is associated with a response rate (RR) of 42%, rising to 64% for combination treatment w